Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Current Deferred Revenue (2025)

Historic Current Deferred Revenue for Universe Pharmaceuticals (UPC) over the last 1 years, with Q3 2025 value amounting to $40.7 billion.

  • Universe Pharmaceuticals' Current Deferred Revenue changed N/A to $40.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 billion, marking a year-over-year change of. This contributed to the annual value of $40.7 billion for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Universe Pharmaceuticals' Current Deferred Revenue is $40.7 billion.
  • Universe Pharmaceuticals' 5-year Current Deferred Revenue high stood at $40.7 billion for Q3 2025, and its period low was $40.7 billion during Q3 2025.